7月8日，Oruka Therapeutics盘中上涨6.18%，报88.265美元/股，成交额1.1亿美元。
消息面上，瑞银近日发布研报指出，Oruka Therapeutics核心银屑病候选药物ORKA-001下半年将公布的28周疗效数据有望进一步降低项目风险。瑞银预计ORKA-001的PASI100应答率将从第16周的约63%提升至第28周的70%-80%，优于艾伯维旗下Skyrizi的同期表现。此外，瑞银认为初步一年期持久性数据将为该药物实现半年或年度给药方案提供早期信号，预计相关更新将于第三季度末或第四季度发布。瑞银同时指出，艾伯维拟收购Apogee Therapeutics一事也验证了ORKA-001所基于的YTE平台价值。该公司此前已完成7亿美元增发融资，现金储备充足，为后续临床推进提供保障。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.